BTBD11

Across TCGA pan-cancer cohorts, BTBD11 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated BTBD11 data layer compared with 6 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTBD11 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTBD11 expression acts as an unfavorable survival marker, although some lineages such as ACC and PAAD show a favorable association.

LUAD, UVM, and ACC are the cancer types where BTBD11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.399	0.744	<.001	73	view →
UVM	DFS	Quartile	All	0.401	0.737	.003	52	view →
ACC	OS	Tertile	II,III,IV	0.874	0.607	.001	50	view →
KIRC	DFS	Tertile	All	0.731	0.851	<.001	50	view →
PAAD	OS	Quartile	All	0.801	0.453	.001	32	view →
LAML	DFS	Tertile	All	0.575	0.333	.011	24	view →
STAD	DFS	Median	III,IV	0.224	0.584	<.001	23	view →
BLCA	OS	Tertile	All	0.494	0.637	.004	22	view →
SARC	OS	Median	All	0.648	0.805	.008	12	view →
READ	DFS	Tertile	All	0.283	0.877	.004	12	view →
PRAD	DFS	Tertile	All	0.959	0.890	.005	12	view →
CHOL	DFS	Median	III,IV	0.647	0.127	.006	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

BTBD11–LUAD (DFS)

Open the LUAD breakdown →